Applications Invited for Pfizer Research Grant: Health Services Research to Improve Management of mBC Patients Treated with Tucatinib

Follow us@ngobox

About the Organization

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer health care products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

About the Grant

The intent of this RFP is to support Investigator Sponsored/General Research projects that will implement and assess the impact of therapy management approaches for patients with HER2+ Metastatic Breast Cancer (mBC) receiving tucatinib in combination with trastuzumab and capecitabine.

Project Types and Area of Interest:

Organizations are invited to submit proposals for initiatives that will implement innovative and community-accessible approaches to improving therapy management with the 3-drug regimen of tucatinib, trastuzumab and capecitabine, including increasing patients’ understanding, quality of life, or adherence to treatment and/or facilitate follow-up or symptom management in daily clinical practice. Projects should be aimed at improving patient care and outcomes using a research framework or “Health Services Research” type approach to evaluate and assess the impact of the interventions.

Funding Range and Project Length:

• Individual projects requesting up to $250,000 will be considered.
• 18-month suggested project length (may be shorter or longer)

Eligibility

Geographic Scope/Location of Project/Study: Global

Applicant Eligibility Criteria:

• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
• The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a terminal degree in Pharmacy, Social Work, or other relevant discipline.
• The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
• The PI must be an employee or contractor of the requesting organization.
• Requesting organization must be legally able to receive award funding directly from Pfizer Inc.

How to Apply

Grant Application due date: Thursday, January 30, 2025.

Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]

• Click the "Start a New Research Grant Application" button.
• In the application:
• For the question “Competitive Grant?” select Yes
• Select the following Competitive Grant Program Name: 2024 ONC Global tucatinib therapy management RES
• Select the following Primary Area of Interest: Oncology - Breast
• Requirements for submission: Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field.
• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

For more information please check the Link

Stay in the loop with the newest RFPs and Grants through NGOBOX's WhatsApp Channel. Join now by clicking here!

Tags Healthcare and Healthtech Research Others